Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$37.11 USD
-0.39 (-1.04%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $37.09 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Cash flow Statements
Fiscal Year End for Collegium Pharmaceutical, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 48.16 | -25.00 | 71.52 | 26.75 | -22.72 |
Depreciation/Amortization & Depletion | 148.02 | 138.94 | 68.92 | 61.55 | 15.48 |
Net Change from Assets/Liabilities | 21.73 | -12.71 | 13.49 | -25.30 | 18.18 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 56.84 | 23.01 | -50.36 | 30.94 | 16.84 |
Net Cash From Operating Activities | 274.75 | 124.23 | 103.56 | 93.94 | 27.78 |
Property & Equipment | -0.46 | -1.62 | -1.94 | -5.55 | -6.44 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -572.07 | 0.00 | 0.00 | 0.00 |
Investments | -70.35 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -368.23 | 0.00 |
Net Cash from Investing Activities | -70.81 | -573.69 | -1.94 | -373.77 | -6.44 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -65.90 | -1.92 | -35.15 | 7.34 | 2.86 |
Issuance (Repayment) of Debt | -65.92 | 442.68 | -50.00 | 281.39 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -8.36 | -4.04 | -4.15 | -2.26 | -0.82 |
Net Cash from Financing Activities | -140.18 | 436.72 | -89.30 | 286.47 | 2.04 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 63.76 | -12.74 | 12.31 | 6.64 | 23.39 |
Cash at Beginning of Period | 176.24 | 188.97 | 176.66 | 170.02 | 146.63 |
Cash at End of Period | 239.99 | 176.24 | 188.97 | 176.66 | 170.02 |
Diluted Net EPS | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 |
Fiscal Year End for Collegium Pharmaceutical, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 47.32 | 27.71 | 48.16 | 16.22 | -4.42 |
Depreciation/Amortization & Depletion | 69.76 | 35.02 | 148.02 | 113.13 | 76.54 |
Net Change from Assets/Liabilities | -7.83 | -5.62 | 21.73 | 23.83 | 15.01 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.09 | 4.82 | 56.84 | 48.24 | 40.26 |
Net Cash From Operating Activities | 129.34 | 61.94 | 274.75 | 201.41 | 127.39 |
Property & Equipment | -0.84 | -0.57 | -0.46 | -0.30 | -0.23 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -26.20 | -17.56 | -70.35 | -45.42 | -41.66 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -27.03 | -18.13 | -70.81 | -45.72 | -41.89 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -24.72 | 4.56 | -65.90 | -44.14 | 5.27 |
Issuance (Repayment) of Debt | -124.89 | -45.83 | -65.92 | -20.08 | 25.75 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -18.75 | -12.87 | -8.36 | -8.13 | -7.96 |
Net Cash from Financing Activities | -168.35 | -54.15 | -140.18 | -72.35 | 23.06 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -66.05 | -10.34 | 63.76 | 83.34 | 108.56 |
Cash at Beginning of Period | 239.99 | 239.99 | 176.24 | 176.24 | 176.24 |
Cash at End of Period | 173.94 | 229.66 | 239.99 | 259.58 | 284.80 |
Diluted Net EPS | 0.52 | 0.71 | 0.93 | 0.53 | 0.34 |